You've chosen Americas as your location.

To clear your location selection and return to IPS Global, click below.

Return to IPS Global

You've chosen Americas as your location.

Thank you for choosing a location. This will help us show you the information that matters the most to you.

Continue Change Selection
Insights

Getting to Grips With mRNA

Insights

Getting to Grips With mRNA

Walking through the mRNA manufacturing process – and its many challenges

By Catherine Jomary | 

The groundwork of over three decades of mRNA research laid the foundations for the successful manufacture of the mRNA-based vaccines for SARS-CoV-2 – the first commercial realization of the technology. Going forward, mRNA technology will not only help the development of other vaccines for infectious diseases, but also address non-viral gene and cell therapy applications for diseases with unmet needs. The strong safety benefit of mRNA resides in the fact that it does not integrate into the human genome.

The process of producing mRNA from a DNA template is cell-free and scalable, but plasmid DNA (pDNA) manufacturing requires microbial fermentation. Even synthetic DNA synthesis requires pDNA as the starting material. The full manufacturing process from DNA template to mRNA encompasses three main stages.

Read the full article on The Medicine Maker website.

Choose Your Location

To customize your experience, select an IPS region or country to view specific information based on your location.

  • Americas
  • United States
  • Canada
  • Brazil
  • All Other Countries

You’ve chosen as your location.

Thank you for choosing a location. This will help us show the information that means to most to you. Continue to the homepage to view featured projects, and happenings specific to your location.

Continue

We use cookies to personalize and enhance your experience on our site. Visit our Privacy Policy to learn more.